Every material Form 8-K Natera, Inc. has filed with the SEC since July 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Natera reported third-quarter 2026 revenue of $794.0 million, up 34.1% from $592.2 million a year earlier, and its net loss narrowed to $59.9 million, or $(0.42) per diluted share, from $87.5 million, or $(0.64) per share. The company raised its 2026 revenue guidance by $140 million at the midpoint, to $3.005 billion to $3.035 billion, which points to higher sales expectations for shareholders, though the company still reports a net loss.
Total revenues were $794.0 million in Q3 2026 versus $592.2 million in Q3 2025, an increase of 34.1%.
Net loss was $59.9 million, or $(0.42) per diluted share, compared with $87.5 million, or $(0.64) per share, in Q3 2025.
2026 total revenue guidance raised to $3.005 billion to $3.035 billion from $2.850 billion to $2.910 billion.
Tests processed rose to approximately 1,093,100 from approximately 893,600, an increase of 22.3%.
Natera reported second-quarter 2026 total revenue of $752.8 million, up 37.7% from $546.6 million a year earlier, and its net loss narrowed to $67.0 million, or $0.47 per diluted share, from $100.9 million, or $0.74 per share. The company raised its 2026 annual revenue guidance by $100 million at the midpoint, to $2.85 billion to $2.91 billion, which signals stronger expected top-line growth for shareholders.
Total revenue was $752.8 million in Q2 2026, up 37.7% from $546.6 million in Q2 2025.
Gross margin was 64.5%, up from 63.4% a year earlier; operating expenses rose 21.5% to $555.3 million.
Net loss was $67.0 million, or $0.47 per diluted share, versus $100.9 million, or $0.74 per share, in Q2 2025.
2026 revenue guidance raised to $2.85 billion to $2.91 billion from $2.74 billion to $2.82 billion.
Natera director Monica Bertagnolli notified the board on July 1, 2026, that she would resign from the board and all its committees, effective the same day, citing a new position with the National Academy of Medicine. The filing states her resignation did not stem from any disagreement with the company on its operations, policies or practices.
Monica Bertagnolli resigned from the Natera board and all committees, effective July 1, 2026
Reason given: new position with the National Academy of Medicine
Filing states no disagreement with the company on operations, policies or practices
Disclosed in Form 8-K dated July 6, 2026, signed by CFO Michael Brophy
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Natera, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →